(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2...cent research has revealed that gene mutations tha...ent of cases of Rett syndrome (RTT) in females are... has refuted previous assumptions, and can occur s...tory of the disorder. A study published in the jou...
...ployers need to take serious and immediate steps t...to HIV/AIDS // , especially for women employees, r...shop today. Respresentatives of trade unions, hum... businesses and various NGOs who participated in a...
...ople with type-1 diabetes are more prone to develo...betic people, a Denmark study reveals.// Both typ...e the body builds up an aberrant immune response a...cing cells in patients with diabetes, and the myel...
...e Public Health Ministry of Bangkok had as of yest...n suspected of having contracting the deadly H5N1 ...hat they were simply suffering from common flu. C... were earlier suspected of having bird flu were su...
Other Medicine News:Health News:Gene Mutations Causing Rett Syndrome Occur in Both Sexes 2Health News:Gene Mutations Causing Rett Syndrome Occur in Both Sexes 3(Date:9/3/2008)...BURG, Md., Sept. 3 /- Panacea Pharmac.... Patent Number 7,413,737 covering,antibodies agai...(HAAH), a,proprietary human cancer biomarker and t... in collaboration with the Massachusetts Institute...rldwide rights to this patent,for development of h...
(Date:9/3/2008)... Company to Discuss Phase 3 Plans with FDA, P...apeutics, Inc.,announced today that it successful...pment of the company,s new, innovative low-dose, o... refers to by its internal product,code AG-200-15....ly met its,primary endpoint of ovulation suppressi...
(Date:9/3/2008)...cal Trial Reconfirms Strong Evidence Pycnogenol(R)...g Effect on Joints Following Cessation ...ept. 3 /- According to the Center for...ommon type of arthritis,is on the rise. A new stu...,Research, reveals Pycnogenol(R), bark extract fro...
(Date:9/3/2008)...Germany, Sept. 3 /- A sub-a...d that treatment with prasugrel,compared with clop...ecurrent heart attacks (7.4 percent vs. 9.7 percen...urred around the time of an artery-opening,procedu...I), or if they,occurred spontaneously during the l...
Breaking Medicine Technology:Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6PRA International Announces New Office Opening in Mumbai 14728 1PRA International Announces New Office Opening in Mumbai 14728 2Food insecurity linked with HIV AIDS in Africa 14725 1Food insecurity linked with HIV AIDS in Africa 14725 2Genzyme Withdraws Bioenvisions European Filing of Evoltra 28R 29 in Elderly AML Patients 4085 1Genzyme Withdraws Bioenvisions European Filing of Evoltra 28R 29 in Elderly AML Patients 4085 2Genzyme Withdraws Bioenvisions European Filing of Evoltra 28R 29 in Elderly AML Patients 4085 3Floating a big idea 3A MIT demos ancient use of rafts to transport goods 2548 1Floating a big idea 3A MIT demos ancient use of rafts to transport goods 2548 2Floating a big idea 3A MIT demos ancient use of rafts to transport goods 2548 3Floating a big idea 3A MIT demos ancient use of rafts to transport goods 2548 4...CISCO, March 19, 2007 /PRNewswire-FirstCall/ --,Me...lts from its,randomized, double-blinded, placebo-c... patients with mild-to-moderate Alzheimer,s,diseas...were,significantly improved compared to patients t...ed, which assessed cognitive function,memory, abi...
... HEIGHTS, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Ny...y announced positive,results from its newly comple...prostatic hyperplasia (BPH). 26 clinical trial sit...ticipated in the,blinded, placebo controlled study... outcome 8-19,months after NX-1207 treatment. Over...
Other Medicine Technology:Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference 2Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference 3Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference 4Nymox Announces Positive Results from Newly Completed Long-term,Study of NX-1207 for Benign Prostatic Hyperplasia 2Nymox Announces Positive Results from Newly Completed Long-term,Study of NX-1207 for Benign Prostatic Hyperplasia 3Inquire
...lly inspects your equipment upon arrival. Our tech...d provides you with a thorough customer quote. We ...get so well help you prioritize repairs. With cust...., , ISI uses only OEM or widely approved equi...
The Infinity™ ALT single liquid stable reagent is intended for the in vitro quantitative determination of ALT in serum. , Infinity™ ALT reagent patented formulation not only provides ex
...owder reagent is intended for the in vitro quantit...ALT (GPT) powder reagent patented formulation not ...ed and convenience, but ensures excellent precisio...gent is suitable for manual use or on automated cl...
Medicine Products: